Complete financial analysis of Arcutis Biotherapeutics, Inc. (ARQT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcutis Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sarissa Resources Inc. (SRSR) Income Statement Analysis – Financial Results
- Authentic Holdings, Inc. (AHRO) Income Statement Analysis – Financial Results
- Ford Motor Company 6.500% Notes (F-PD) Income Statement Analysis – Financial Results
- Immersion Corporation (IMMR) Income Statement Analysis – Financial Results
- Xiamen Amoytop Biotech Co., Ltd. (688278.SS) Income Statement Analysis – Financial Results
Arcutis Biotherapeutics, Inc. (ARQT)
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 59.61M | 3.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.99M | 754.00K | 763.00K | 455.00K | 195.00K | 0.00 | 0.00 |
| Gross Profit | 54.62M | 2.93M | -763.00K | -455.00K | -195.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 91.63% | 79.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 110.58M | 182.44M | 145.56M | 115.31M | 36.52M | 17.94M | 3.41M |
| General & Administrative | 0.00 | 122.12M | 60.97M | 21.34M | 6.61M | 1.80M | 695.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 185.15M | 122.12M | 60.97M | 21.34M | 6.61M | 1.80M | 695.00K |
| Other Expenses | 0.00 | 5.82M | 173.00K | 967.00K | 1.14M | 480.00K | -872.00K |
| Operating Expenses | 295.72M | 304.56M | 206.53M | 136.65M | 43.13M | 19.74M | 4.11M |
| Cost & Expenses | 300.71M | 305.31M | 206.53M | 136.65M | 43.13M | 19.74M | 4.11M |
| Interest Income | 0.00 | 9.83M | 173.00K | 967.00K | 1.14M | 0.00 | 0.00 |
| Interest Expense | 29.71M | 15.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.88M | 1.25M | 763.00K | 455.00K | 195.00K | 19.74M | 4.11M |
| EBITDA | -227.43M | -294.55M | -205.59M | -135.22M | -41.80M | 480.00K | -872.00K |
| EBITDA Ratio | -381.56% | -8,025.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -241.10M | -301.63M | -206.53M | -136.65M | -43.13M | -19.74M | -4.11M |
| Operating Income Ratio | -404.49% | -8,183.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -17.93M | -9.83M | 173.00K | 967.00K | 1.14M | 480.00K | -872.00K |
| Income Before Tax | -259.03M | -311.46M | -206.36M | -135.68M | -42.00M | -19.26M | -4.98M |
| Income Before Tax Ratio | -434.57% | -8,449.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.11M | 9.83M | -454.00K | -84.30K | 23.14K | -480.00K | -4.11M |
| Net Income | -262.14M | -321.29M | -205.90M | -135.68M | -42.00M | -19.26M | -4.98M |
| Net Income Ratio | -439.79% | -8,716.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.78 | -5.84 | -4.17 | -3.80 | -1.10 | -0.53 | -0.14 |
| EPS Diluted | -3.78 | -5.84 | -4.17 | -3.80 | -1.10 | -0.53 | -0.14 |
| Weighted Avg Shares Out | 69.31M | 55.03M | 49.41M | 35.67M | 38.09M | 36.24M | 36.24M |
| Weighted Avg Shares Out (Dil) | 69.31M | 55.03M | 49.41M | 35.67M | 38.09M | 36.24M | 36.24M |
Have $5-10? 7 Affordable Stocks That Are About to Breakout.
Investors with any experience in the world of penny stocks know that risk is real. That risk is higher as the price of shares goes lower.
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflumilast cream 0.15% in both the 4-week parent study and the 52-week open...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 57,500 restricted stock units of Arcutis' common...
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Head of Investor Relations Frank Watanabe - President and Chief Executive Officer Todd Edwards -...
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs.
Cheap Stocks To Buy: Should You Watch These 5 Growth Stocks? Cipher Mining Works On A New Base
Heritage shares have cut through that price resistance like a hot knife through butter.
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation data Crodafos™ CES, used in ZORYVE foam, is suitable...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 160,500 restricted stock units of Arcutis' common...
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2024 financial results and provide a business update...
Source: https://incomestatements.info
Category: Stock Reports